StockDrifts LogoStockDrifts

Hwanin Pharmaceutical 016580

Company
환인제약Hwanin Pharmaceutical
Insiders
0
Buys
0
Total Value
—
Avg Return
—
Last Filing
2025-10-30

Hwanin Pharmaceutical (016580) has 0 disclosed insider purchases and 0 disclosed disposals on record, filed by 0 distinct insiders. The earliest filing StockDrifts holds for Hwanin Pharmaceutical is dated 2025-10-30; the most recent is 2025-10-30.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2025-10-30SELL증여
이광식
Gwangsik Lee
CEO Chairman-1.9M₩11,340+0.4%₩21.1B ($14.6M)
2025-10-30BUY수증
이원범
Wonbeom Lee
CEO and President1.9M₩11,340-0.4%₩21.1B ($14.6M)

Frequently asked questions

Who has been buying Hwanin Pharmaceutical stock?
0 distinct insiders have filed 0 disclosed insider purchases in Hwanin Pharmaceutical (016580), most recently on 2025-10-30. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Hwanin Pharmaceutical have?
Hwanin Pharmaceutical has 0 buy-side and 0 sell-side disclosures on record, spanning 2025-10-30 to 2025-10-30.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.